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NMZ developed at University of Missouri
Proprietary Formulations: Patent Pending (4 Countries)
NPV,  US Patent number : 10/931,174
Exclusively licensed to Nanoparticle Biochem, Inc (NBI) 
BACTERIA ON INDWELLING
MEDICAL DEVICE
MICROBES AFTER 
WASHING HAND
 Microbes in hand: H1N1 flu and 
spread of disease.
 Biofilm: FDA says biofilm is a 
significant cause of hospital-acquired 
infections and related deaths. CDC 
HARMFUL MICROBES IN YOUR DAILY LIFE 
BLEACH DOES NOT KILL MOLD!
says biofilm is responsible for 65% of 
all hospital-acquired infections.
 Molds:  Produce airborne toxins lead 
to breathing difficulties, memory and 
hearing loss, dizziness, flu-like 
symptoms, and acid reflux.
MARKET POTENTIAL
 Surface Antimicrobial: Health and Hygiene monitoring report that bacterial infections in 
human populations across the globe is increasing at an alarming pace of 15-20% year by 
year (Source: 2009 Health and hygiene report).
Market Potential : $ 25 billion (Frank and Sullivan).
 Biofilm Antibacterial: 1 in 20 patients hospitalized will develop biofilm related infection. 
This costs $38,600 for hospital care and $58,000 for post-operative care per patient. 
(Source: Infection rate today, 8, 2004, 32).
Market Potential: $ 2 billion (Frank and Sullivan) and growing 20% every year.
 Antimold: According to the Centre for Disease Control (CDC), ~1.7 million mold related 
diseases happen each year in the US alone. Eradication of mold is clearly an unmet hygienic 
need of global proportions. In US, the problem is acute (Source: CDC) Market Potential: $ 
500 million (Frank and Sullivan).
 Multi-Surface Antibacterial, Antiviral, and Antifungal
 Kills Bacteria in Biofilms –the only technology of this 
kind in the world
 Removes Mold and Prevents Recurrence
ANTIMICROBIAL 
PLATFORM TECHNOLOGY
NMZ : PROTECTION AGAINST HARMFUL MICROBES
 Proprietary Formulations: Patent Pending
 Patent is protected in the U.S. and other countries 
including Germany, Japan, and Canada
 Developed at MU and licensed to Nanoparticle 
Biochem, Inc. 
NMZ : APPLICATIONS
 Acts in less than 30 seconds.
 Removes microbes and protect the surface.
 No chlorine. Water based and ideal for use in 
health care facilities, hospitals, schools, restaurants,
restrooms and public places
NMZ inside
NMZ inside
 Penetrates impenetrable bacterial biofilms, where traditional anti bacterial 
agents failed to be effective.
 Prevents and destroys germs in slippery biofilms to give a clean and disinfected 
surface.
 Easy to use spray applicator.
NMZ inside
 Eradicates and prevents mold growth.
 Non-toxic, no fumes, and water based.
 Ideal for use in schools, public/private dwellings, and flood affected areas
NMZ : SALES AND DISTRIBUTION PLAN
NMZ concentrate 
Two approaches:
Bottling plant Broker
For ex, AFM
Production 
facility in 
Missouri
Distributor
NMZ inside
supply to strategic 
partner
Add value to existing product line
NMZ : COMPETITIVE LANDSCAPE
Ease of use
High
Against biofilms
Low High
NBI will manufacture the NMZ agents in its facility in Missouri.  
However, marketing and distribution will be handled through INDUSCO.
A long term contract will be signed by these two companies.  
Revenue Estimate: Joint venture between NBI and investor.
Revenue Sharing: 50% each between NBI and investor.
NBI Role: Technology sharing, QC, continuous product upgrade. Investor 
Role: Marketing and Distribution.
NMZ : BUSINESS MODEL
Production    = $0.20
R & D Legal   =  $ 0.10
Distribution  =  $ 0.20
Marketing     =  $0.20
Admin            =  $0.05
Broker            =  $0.05
Royalty          =  $0.05
Profit              =  $0.25
Transport       =  $0.05
Supermark =  $0.10
Price per Gallon = $1.25
NANOMOLD ZAPPER (NMZ) WILL BE SUPPLIED IN 1 GALLON QUANTITIES
ZONE
SALES PREDICTION: NO OF NMZ UNITS TO BE SOLD
REVENUE NBI’S REV. Investors Rev.
EAST COAST 13,000,000 6,500,000 6,500,000
MIDWEST 11,000,000 5,500,000 5,500,000
NORTH/SOUTH 10,500,000 5,250,000 5,250,000
WEST COAST 13,000,000 6,500,000 6,500,000
CALIFORNIA 12,500,000* 6,250,000 6,250,000
*California state regulations do not allow the sales to commence after conditional 
approval from US EPA. 
EXPECTED REVENUE FOR 
NMZ FOR FIRST YEAR OF 
COMMERCIALIZATION: 
$60 MILLION
(Calculated on basis of 1% 
market penetration)
NMZ : CURRENT STAGE
Basic
research
Proof-of-concept 
Commercial 
scale
Toxicity 
in small 
and large 
animals
Dermal 
toxicity
Aquatic 
toxicity
Conditional 
approval from 
EPA
Commercialization 
of NMZ
November August 
Investment Required
May 2006 June 2007
2007
Jan 2008
2008
2009-2010 2011 2012
Funded by UM’s 
Fast Track Economic 
Development
Program
Funded by State and Federal funds
NMZ : INVESTMENT OPPORTUNITY
 $5 MILLION –INVESTMENT; MILE STONE BASED; 1YEAR
 INVESTMENT FOR CONDITIONAL EPA APPROVAL PROCESS AND PRODUCTION PLANT 
 50 % OWNERSHIP STAKE 
 NO ADDITIONAL ROUNDS OF INVESTMENT NEEDED
 RETURN FOR INVESTMENT:
2ND YEAR BREAK EVEN; AFTER 3RD YEAR MORE THAN 50 % RETURN
(5 YEAR IRR OVER 90%)
NMZ : TEAM
Professor Henry White
CEO
Nanoparticle Biochem, Inc
Professor Kattesh Katti
Curators’ Professor, UM
More than 30 years of experience.  Discovery 
stage to commercial market. 
More than 25 years of experience in product 
development and research.  Project leader.  
Discovery stage to commercial market. 
More than 15 years of experience in research.  
Working towards commercialization of products.  
Track record of bringing investment to NBI.  
Dr. Raghuraman Kannan
Assistant Professor of 
Radiology
More than 15 years of experience in chemistry.  
Directing research division at NBI.  Two SBIR Phase I 
contract and One SBIR Phase II contract. 
More than 20 years of experience in inorganic and 
radiochemistry.  Expert in analytical chemistry for 
quality control
Independent antimicrobial efficacy analysis: US Defense Labs, ND.  
Ms. Kavita Katti
Senior Scientist, UM
Dr. Anandhi Upendran
Director of Research
Nanoparticle Biochem, Inc
